Your browser doesn't support javascript.
loading
Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma.
Zhang, Xi-Bao; Zhang, San-Quan; Li, Chang-Xing; Huang, Zhen-Ming; Luo, Yu-Wu.
Afiliación
  • Zhang XB; Guangzhou Institute of Dermatology, Guangzhou, China;
  • Zhang SQ; Guangzhou Institute of Dermatology, Guangzhou, China;
  • Li CX; Dongguan Institute of Dermatology, Dongguan, China.
  • Huang ZM; Guangzhou Institute of Dermatology, Guangzhou, China;
  • Luo YW; Guangzhou Institute of Dermatology, Guangzhou, China;
Dermatol Reports ; 2(1): e4, 2010 Jan 18.
Article en En | MEDLINE | ID: mdl-25386240
Retinoids have been used for years as monotherapy and/or in combination for treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, or cutaneous T-cell lymphoma (CTCL) basal cell carcinoma (BCC). We report 4 cases with BCC confirmed by histopathology who were treated by short-term systemic acitretin combined with retinoic acid 0.1% cream. The 4 cases with BCC showed good response to the treatment without severe adverse effects during treatment and follow-up. The finding suggests that acitretin may be an appropriate treatment option for elderly patients who require less invasive treatment for BCC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Reports Año: 2010 Tipo del documento: Article Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Reports Año: 2010 Tipo del documento: Article Pais de publicación: Italia